Safety and Efficacy of Amphotericin B Lipid Complex in the Treatment of Cryptococcal Meningitis in Patients With the Acquired Immunodeficiency Syndrome

Inclusion Criteria Concurrent Medication: Allowed: * Intravenous pentamidine for treatment of Pneumocystis carinii pneumonia (PCP) but not for prophylaxis. Patients must have the following: * Meet the CDC criteria for diagnosis of AIDS. * Confirmed episode of acute cryptococcal meningitis. * Informed consent of the patient or guardian prior to entry. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: * Clinical evidence of acute or chronic meningitis due to an agent other than Cryptococcus neoformans. * History of hypersensitivity/anaphylactoid reaction attributed to amphotericin B. * Any other concomitant condition which, in the opinion of the investigator, would preclude a patient's participation in the study. Concurrent Medication: Excluded: * Corticosteroids. * Salicylates or other drugs known to interfere with prostaglandin synthesis except as specified in protocol. * Zidovudine. * Investigational agents. * Interferon. * Interleukin-2 (IL-2). * Steroids. * Isoprinosine. * Intrathecal Amphotericin B. * Intravenous Pentamidine PCP prophylaxis (only treatment). Patients with the following are excluded: * Clinical evidence of acute or chronic meningitis due to an agent other than Cryptococcus neoformans. * History of hypersensitivity/anaphylactoid reaction attributed to amphotericin B. * Inability to obtain appropriate follow-up visits. * Any other concomitant condition which, in the opinion of the investigator, would preclude a patient's participation in the study. Prior Medication: Excluded within 4 weeks of study entry: * Amphotericin B. * Excluded within 2 weeks of study entry: * Any other experimental drug.